Drug Profile

TQF 3250

Alternative Names: TQF-3250

Latest Information Update: 02 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chia Tai Tianqing Pharmaceutical Group
Class Antihyperglycaemics; Obesity therapies; Small molecules
Mechanism of Action Glucagon-like peptide-1 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Type 2 diabetes mellitus
Preclinical Obesity

Most Recent Events

22 Jan 2026 Pharmacodynamics and adverse event data from a preclinical trial in Type 2 diabetes mellitus released by Sino Biopharmaceutical
18 Dec 2025 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in China (PO) (NCT07327281)
01 Dec 2025 The US FDA approves the clinical trial application for TQF 3250 for Obesity (PO, Capsule)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com